Elevai Labs Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
| (a) | The following documents are filed as part of this report: |
|---|
| (1) | Financial Statements: |
The audited balance sheet of the Company as of December 31, 2023, the related statements of operations and comprehensive loss, changes in stockholders’ equity and cash flows for the year then ended, the footnotes thereto, and the report of TPS Thyer, independent auditors, are filed herewith.
| (2) | Financial Schedules: |
None
Financial statement schedules have been omitted because they are either not applicable or the required information is included in the financial statements or notes hereto.
| (3) | Exhibits: |
The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Report.
| (b) | The following are exhibits to this Report and, if incorporated by reference, we have indicated the document previously filed with the SEC in which the exhibit was included. |
|---|
Certain of the agreements filed as exhibits to this Report contain representations and warranties by the parties to the agreements that have been made solely for the benefit of the parties to the agreement. These representations and warranties:
| ● | may have been qualified by disclosures that were made to the other parties in connection with the negotiation of the agreements, which disclosures are not necessarily reflected in the agreements; |
| ● | may apply standards of materiality that differ from those of a reasonable investor; and |
| ● | were made only as of specified dates contained in the agreements and are subject to subsequent developments and changed circumstances. |
Accordingly, these representations and warranties may not describe the actual state of affairs as of the date that these representations and warranties were made or at any other time. Investors should not rely on them as statements of fact.
| Exhibit Number | Description |
| 3.1 | Form of Third Amended and Restated Certificate of Incorporation of Elevai Labs Inc. (incorporated by reference to Exhibit 3.3 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 4.1 | Form of Common Stock Share Certificate (incorporated by reference to Exhibit 4.1 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 4.2 | Description Of Registered Securities |
| 10.1+ | 2020 Equity Incentive Plan, as amended, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.2 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 10.2 | Form of Amended and Restated Consulting Agreement between Elevai Labs, Inc. and NorthStrive Companies Inc. (incorporated by reference to Exhibit 10.3 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 10.3 | Form of Advisory Agreement between Elevai Labs, Inc. and Braeden Lichti (incorporated by reference to Exhibit 10.4 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 10.4† | Authorized Distributor Agreement, dated August 30, 2022, between Elevai Labs, Inc. and Refine USA, LLC (incorporated by reference to Exhibit 10.6 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 10.5† | Authorized Distributor and Trademark License Agreement, dated January 17, 2022, between Elevai Labs, Inc. and Dermapenworld Pty Ltd (incorporated by reference to Exhibit 10.7 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 10.6† | Collaboration Agreement, dated November 28, 2023, by and between the Company and Yuva BioSciences, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A, filed with the SEC on December 5, 2023). |
| 10.7† | License Agreement, dated January 16, 2024, by and between the Company and INmune Bio, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on January 22, 2024). |
| 10.8+† | Employment Agreement of Jordan R. Plews, dated September 26, 2021 |
| 10.9+† | Employment Agreement of Brenda Buechler, dated June 24, 2022 |
| 10.10+† | Employment Agreement of Chris Kraneiss, dated August 6, 2022 |
| 14.1 | Code of Ethics (incorporated by reference Exhibit 14.1 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 19. | Elevai Insider Trading Policy |
| 21.1 | List of Subsidiaries. (incorporated by reference Exhibit 21.1 to the Company’s registration statement on Form S-1, filed with the SEC on September 28, 2023). |
| 24.1 | Powers of Attorney (the signature page to this registration statement) |
| 31.1 | Certification of Principal Executive Officer required by Rule 13a-14(a). |
| 31.2 | Certification of Principal Financial Officer required by Rule 13a-14(a). |
| 32.1 | Certification required by Section 1350 of Chapter 63 of Title 18 of the United States Code. |
| 97 | Elevai Policy Related to Recovery of Erroneously Awarded Compensation |
| 101. INS | Inline XBRL Instance Document. |
| 101. SCH | Inline XBRL Taxonomy Extension Schema Document. |
| 101. CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101. DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 101. LAB | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101. PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
| † | Information in this exhibit identified by brackets is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) the type the Company treats as private or confidential. |
|---|
| + | Management contract or compensatory plan |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.